MONTREAL, Sept. 7,
2023 /CNW/ - Valeo Pharma Inc. (TSX: VPH) (OTCQB:
VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a
Canadian pharmaceutical company, announced today that it will
report its financial results and highlights for the third quarter
ended July 31, 2023 on Wednesday September 13, 2023 after market close.
The Company will host a conference call to discuss those results
and highlights on Thursday September 14,
2023 at 8.30am (ET).
To join the conference call without operator assistance, you may
register and enter your phone number at
https://emportal.ink/3P5vSSr to receive an instant automated call
back.
You can also dial direct to be entered to the call by an
Operator. (Traditional conference call instructions
here):
Conference ID:
|
31187641
|
Date:
|
Thursday, September 14,
2023
|
Time:
|
8:30am ET
|
Dial-in numbers:
|
1-888-664-6392 or
416-764-8659
|
Audio replay
numbers:
|
1-888-390-0541 or
416-764-8677
|
Replay code:
|
187641 #
|
A live audio webcast of the conference call will be available
via:
https://app.webinar.net/Kz8w4Eg367j
About Valeo Pharma Inc.
Valeo Pharma is a fast growing Canadian pharmaceutical company
dedicated to the commercialization of innovative prescription
products in Canada with a focus on
Respiratory/Allergy, Ophthalmology and Hospital Specialty Products.
Headquartered in Kirkland, Quebec
Valeo Pharma has all the required capabilities and the full
infrastructure to register and properly manage its growing product
portfolio through all stages of commercialization. For more
information, please visit www.valeopharma.com and follow us on
LinkedIn and Twitter.
Forward Looking
Statements
This press release contains forward-looking statements about
Valeo's objectives, strategies and businesses that involve risks
and uncertainties. These statements are "forward-looking" because
they are based on our current expectations about the markets we
operate in and on various estimates and assumptions. Actual events
or results may differ materially from those anticipated in these
forward-looking statements if known or unknown risks affect our
business, or if our estimates or assumptions turn out to be
inaccurate.
SOURCE Valeo Pharma Inc.